

1 **Title:** Effects of primary-care led self-management and low carbohydrate diet on
2 glycaemic control in individuals with type 2 diabetes mellitus: study protocol of a cluster
3 randomised controlled trial.

4 **Running Title:** Effects of self-management and low carbohydrate dietary adherence in
5 type 2 diabetes

6 **Authors**

7 Joshua Chadwick^{1*}, P Ganeshkumar¹, Jeyashree Kathiresan¹, Hemant Deepak
8 Shewade¹, Madhanraj K¹, Devika S¹, S Lokesh¹

9 **Affiliation**

10 ¹ICMR-National Institute of Epidemiology (ICMR-NIE), Chennai, India

11

12 **Corresponding author***

13 Dr Joshua Chadwick

14 Scientist-B (Medical),

15 ICMR-National Institute of Epidemiology

16 R-127, TNHB, Ayapakkam, Chennai, Tamil Nadu, India 600077

17 Ph: Off+91 44 26136208; Email: joshuachadwick89@gmail.com

18

19

20 **Manuscript details**

21 **Word count:** Abstract (239 words); main text (2357 words); 1 figure; 18 references

22

23

24 **Abstract**

25 **Introduction** Type 2 diabetes mellitus (T2D) poses a significant global health burden,
26 contributing to mortality and morbidity primarily through its complications such as renal
27 failure, cardiovascular events, and others. Dietary patterns, particularly low
28 carbohydrate diet and diabetes self-management education (DSME) have shown
29 promise in improving glycaemic control and other metabolic parameters. However,
30 evidence on the safety and long-term efficacy of such diets including health education,
31 especially in populations like India with a high carbohydrate dietary tradition, is limited.
32 This paper outlines a randomised controlled trial to determine the effectiveness of
33 adopting a low carbohydrate diet in addition to standard care for T2D patients
34 compared to those following standard care alone.

35 **Methods and analysis** This is a cluster randomized controlled trial that adheres to the
36 Recommendations for Interventional Trials as outlined by the Standard Protocol Items.
37 The study will be conducted in 16 urban primary health centres (UPHCs). UPHCs
38 randomized to either standard care or low carbohydrate diet intervention. Outcome:
39 generating evidence on improving HbA1c levels without increasing anti-hyperglycaemic
40 medication. This will be achieved through the use of CGM technology and personalized
41 nutrition counselling, which will focus on dietary carbohydrate restriction for patients
42 with T2DM.

43 **Discussion:** Results of this study will be published in peer- reviewed journals. The trial
44 will provide insights into the efficacy and feasibility of implementing low carbohydrate
45 diets and DSME in T2D management within public health settings. This protocol is
46 registered on Clinical Trials Registry-India. The registration number for this trial is
47 CTRI/2024/02/062202.

48

49 **Introduction**

50 **With an estimated 1.5 million deaths primarily due to diabetes in 2019, diabetes was**
51 **the ninth most leading cause of mortality.[1] Compared to high-income countries,**
52 **prevalence has been increasing more rapidly in low- and middle-income nations.[2] In**
53 **India, the prevalence of diabetes was 7.3%.[3] The World Health Organization (WHO)**
54 **has identified unhealthy diets and a lack of exercise as risk factors for non-**
55 **communicable diseases.[4]**

56 **Systematic reviews and meta-analyses of randomised control trials (RCTs) suggests low**
57 **carbohydrate diets in T2D may enhance glycaemic control, triglyceride levels, and HDL**
58 **cholesterol profiles.[5–8] In 2020, American Diabetes Association (ADA) standards of**
59 **care for Type 2 Diabetes (T2D) report stated: ‘for individuals with type 2 diabetes not**
60 **meeting glycaemic targets or for whom reducing glucose-lowering drugs is a priority,**
61 **reducing overall carbohydrate intake with a low-carbohydrate or a very-low-carbohydrate**
62 **eating pattern is a viable option’.[9]**

63 **Indian diet has a tradition of relying primarily on carbohydrates, making it increasingly**
64 **challenging to control diabetes.[10] Indians typically consume around 65% of calories**
65 **though carbohydrates and are heavily dependent on their staple grains’**
66 **consumption.[11] However, little is known about the most practical ways to put**
67 **recommendations on lower carbohydrate diets into practice in public primary care**
68 **settings in India.**

69 **Objectives**

70 **The primary objective of the study is to evaluate the effectiveness of intervention model**
71 **for low carbohydrate dietary adherence and diabetes self-management in individuals**

72 with type 2 diabetes mellitus, aiming to enhance the capability for self-management
73 and adherence to a low carbohydrate diet, especially the value of glycated haemoglobin
74 (HbA1c), within the routine primary care setting where individuals with T2D is managed.
75 The secondary objectives are: a) to evaluate the cardio-renal risk variables such as body
76 weight, lipid profile, serum creatinine, blood pressure (BP), homeostatic model
77 assessment for insulin resistance (HOMA IR), effect on diabetes medication prescription
78 and change in the monthly cost of antihyperglycemic agents and any adverse events, b)
79 To describe the meal-related glycaemic fluctuations based on real-time continuous
80 glucose monitoring tool, c) to determine the health-related quality of life (HRQoL) using
81 the global health visual analogue scale (EQ-VHA) and the EuroQol five-dimensional
82 questionnaire (EQ-5D), and d) to evaluate the enablers and barriers of adapting self-
83 management practices and low carbohydrate diet from the perspectives of individual
84 and service provider.

85 **Methods**

86 **Study design**

87 This trial is conducted in accordance with the Standard Protocol Items:
88 Recommendations for Interventional Trials (SPIRIT) as a cluster randomized controlled
89 trial. Recruitment of patients for this yet-to-begin study is scheduled to commence in
90 November 2024. The study will use a cluster-randomised controlled design with a
91 nested mixed-methods process evaluation, with urban primary centres (UPHC) as the
92 unit of randomisation. Randomisation at the UPHC level will prevent contamination
93 between groups and allow consistent advice from project assistant, who will have a
94 background in nursing or life sciences, who will be offering the self-management and
95 dietary advice.

96 The Indian Council of Medical Research (ICMR)-National Institute of Epidemiology,
97 Chennai, will centrally and independently of the study team conduct the zone
98 randomization and the selection of the UPHC (Figure 1). The protocol was reviewed and
99 approved by the Scientific Advisory Committee/ Institutional Human Ethics Committee
100 of the research institution (NIE/IHEC/202302-03) and also approval was obtained from
101 the corporation health officer, Greater Chennai Corporation
102 (P.H.D.No.C6/06658/2023). The study has been registered in the Indian Clinical Trial
103 Registry (CTRI/2024/02/062202).

104 **Study setting**

105 The study will be conducted at UPHCs of Greater Chennai City Corporation, South India.

106 **Targeted population**

107 Individuals with type 2 diabetes who is seeking health care in UPHCs in Greater Chennai
108 city corporation.

109 **Inclusion and exclusion criteria**

110 Individuals over the age of 30 years who have type 2 diabetes with or without comorbid
111 conditions, HbA1c level that is greater than 7.5% during the screening test will be
112 included in this study and those who having terminal illness, mental illness, learning
113 difficulties, diagnosed eating disorder or purging, pregnant/ considering pregnancy in
114 the next 12 months and current use of weight-loss drugs or use of oral glucocorticoids
115 will be excluded.

116 **Recruitment**

117 A total of 320 participants (160 each arm) will be recruited from the selected UPHCs
118 (figure 1). Participants who meet the criteria will be included. Reasons for exclusions

119 will be recorded. Informed consent will be secured from all participants, for 18 months
120 on the trial protocol and indefinite long-term data collection from their medical records
121 and through population health registry.

122 Individual participants will be randomly assigned in a 1:1 ratio to either the intervention
123 or control group. We will ensure that all participants have an equal chance of being
124 allocated to either group to minimize selection bias. To limit attrition and analytical
125 bias, we will use intention-to-treat (ITT) analysis.

126 **Blinding**

127 It will not be possible to blind the investigators or participants to allocation. Those
128 responsible for analysis will be blinded to allocation.

129 **Intervention**

130 Participants in the intervention arm (Zone/UPHCs) of the study will be provided with
131 advice on adopting a low carbohydrate diet (<130 g of carbohydrates/day) and health
132 education for diabetes self-management, in addition to receiving standard medical
133 care. During their regular physician visits, participants will receive dietary advice for a
134 period of 10-20 minutes. They will be recommended to follow a low carbohydrate diet
135 and health education, and a one-on-one visit will be scheduled every 3, 6, 9, and 12
136 months to monitor their progress. Monthly telephonic follow-ups will also be conducted
137 to track their dietary habits. For the first eight weeks, patients will be monitored closely
138 for any signs of hypoglycaemic symptoms, and their blood glucose levels will be
139 checked as required. The control arm will be advised to follow a standard diet, along
140 with the standard diabetes treatment. They will have 10-20-minute 'one-on-one' visits
141 for advice on following a standard diet at baseline, 3, 6, 9, and 12 months.

142 During the initial two weeks, a total of 30 individuals (15 in intervention and control
143 arm) with T2DM will have the opportunity to wear a CGM and keep a log of their diet,
144 hypoglycaemic symptoms, and blood glucose level, which will be checked whenever
145 required. Strategies to improve adherence will be implemented at every visit, including
146 counselling on the importance of adhering to the prescribed diet and medication, as
147 well as guidance on what to do in the event of hyperglycemic episodes.

148 Patients will also be instructed on the purpose and use of the study diet. Challenges
149 encountered during the study will be discussed at each visit, and patients will be
150 informed about contacting the study centre or study physician for any difficulties in
151 following the diet or experiencing symptoms of hyperglycaemia. Patients who
152 experience drug intolerance, diet intolerance, or poor compliance will be documented
153 and included in the intention-to-treat analysis.

154 The Diabetes Plate Method handouts will be used to instruct participants on how to
155 divide the plate. Infographic of balance between sugar intake and output also will be
156 given to study participants (Figure 2). The lower carbohydrate diet sheet will be given
157 which provides a sample diet chart and information on low GI food sources (annex 1).

158 Information on the glycaemic load derived from the glycaemic Index (GI) will be tailored
159 to meet the sociocultural dietary preferences of each participant. This approach aims to
160 encourage a reduction in the consumption of foods high in sugar and starch, such as
161 rice-based dishes like dosa or idly, rice, or bread, and to suggest alternatives including
162 green leafy vegetables, legumes, millets, full-fat dairy products, eggs, meat, fish, guava,
163 berries, and nuts. By doing so, it will equip participants with the knowledge to make
164 healthier food choices by comparing the glycaemic load of different meal options to the
165 glycaemic impact of a standard amount (4 grams) of table sugar per teaspoon.[13]

166 **Sample Size**

167 Evidence from the literature showed that changes in the HbA1c level for three months is
168 0.6 in the Low-Carbohydrate Diet group and 0.3 in the standard diet with the standard
169 deviation of 1.2 and 0.7, respectively.[14] Therefore, we calculated 85 patients for each
170 group, with $\alpha = 0.05$ and power = 0.80. In view of the sample loss of 20% and design
171 effect of 1.5, the number for each group is 153 rounded to 160. Assuming 20 subjects
172 to be enrolled in each UPHC we need 8 UPHC from 2 Zones for each group.

173 **Data collection, management, and analysis**

174 **Baseline assessments and subsequent visits**

175 Baseline measurements of weight and BP along with blood tests such as HbA1c, lipid
176 profiles, creatinine level and HOMA IR. Follow-up will be for a year at 3, 6, 9 and 12
177 months. During the follow-up visits, variables such as body weight, HBA1c levels, BP,
178 lipid profiles and creatinine will be measured. Change in the number of
179 antihyperglycemic medications will be determined by subtracting the total number of
180 antihyperglycemic medications at baseline from the total cost of antihyperglycemic
181 medications during follow-ups.

182 **Diet acceptability, process evaluation and quality of Life**

183 Semi-structured questionnaires will be used to gather information from study
184 participants and their family members through face-to-face interviews at the UPHC or
185 telephone interviews. The questionnaires will focus on their experiences, challenges,
186 facilitators, and strategies for adapting to a low-carbohydrate diet till data saturation is
187 achieved.[15] The intervention group participants will be interviewed three times: once
188 after the use of CGM (continuous glucose monitoring), at months 1 and 12. The control
189 group participants will be interviewed twice, at months 1 and 12. The interviews will be

190 conducted by team members who are trained in semi-structured interviewing
191 techniques, and they will receive regular feedback from a qualitative methodologist.
192 The implementation of the intervention and the ease of engagement will be assessed
193 by a purposive convenience sample of 10 health care professionals (doctors, nurses,
194 and dietitians) who will be providing the intervention, will be interviewed. Quality of Life
195 outcome (EQ-5D-3 L) will be measured at baseline, 6 and 12 months for all participants.

196 **Statistical methods**

197 Descriptive analysis will be performed for all the quantitative variables and the results
198 will be summarised as proportions and mean \pm SD. The primary outcomes, which
199 include changes in HbA1c levels, blood pressure, lipid profiles, creatinine, and body
200 weight between groups, will be analysed using a paired t-test. If the participants
201 withdraw from the intervention will be included in ITT analysis. Additionally, a thematic
202 analysis will be carried out on the qualitative data.

203 **Monitoring**

204 The trial will be supervised by data safety and monitoring board (DSMB). The board
205 composed of 5 members independent of the Investigators, having expertise in diabetes,
206 low carbohydrate diet, nutrition and ethics. DSMB will review the study at
207 predetermined intervals and issue recommendations concerning ongoing study in order
208 to ensure that risks are minimized and benefits are maximised for patients and also the
209 Investigator will ensure that this study is conducted in accordance with Good Clinical
210 Practice.

211 **Data management**

212 The ODK app will be used for quantitative data collection, which will be transferred to
213 the ICMR-NIE server. Qualitative data will be collected through an audio recorder after
214 obtaining consent.

215 **Ethics and dissemination**

216 The Investigator will ensure that this study is conducted in accordance with the
217 principles of the Declaration of Helsinki. The protocol, informed consent form,
218 participant information sheet, any participant facing materials and infographic material
219 has been submitted to Institutional Human Ethics Committee (IHEC) and/or regulatory
220 authorities and have sought the written approval (NIE/IHEC/202302-03).

221 **Consent**

222 A written informed consent shall be obtained from the participant. In the event that the
223 participant or their relative lacks formal education, a thumbprint shall be taken. The
224 Participant Information Sheet (PIS) has been made available in English and Tamil shall
225 provide comprehensive information regarding the study's nature, benefits, implications,
226 limitations, side effects, and risks. The participant shall be free to withdraw their
227 consent or discontinue participation at any time, without any prejudice to future care,
228 and without any obligation to provide a reason.

229 **Confidentiality**

230 The study team will ensure that participants' anonymity will be maintained and their
231 records will be kept confidential. All documents related to the study will be securely
232 stored and accessed only by authorized personnel and the study staff. Patient names
233 and any identifying information will not be entered into any digital file or document,
234 including the eCRF.

235 **Dissemination policy**

236 Findings will be shared with competent authorities such as the Greater Chennai City
237 Corporation and their UPHCs, and will be published in high-impact journals, in
238 accordance with CONSORT guidelines.

239 **Discussion**

240 The management of T2D continues to be a significant global health challenge,
241 particularly in low- and middle-income countries like India. Despite advancements in
242 therapeutic options, glycaemic control in patients remains suboptimal, often due to
243 various socio-cultural, economic, and dietary factors. This cluster-randomised controlled
244 trial aims to address this challenge by examining the effects of a low-carbohydrate diet
245 and diabetes self-management education (DSME) on glycaemic control in individuals
246 with T2D within the primary healthcare setting of Chennai, India. This study seeks to
247 bridge this gap by providing culturally tailored dietary advice tha[16] aligns with the
248 carbohydrate consumption patterns of the Indian population.[16]

249 An important strength of this study is the use of real-time continuous glucose
250 monitoring (CGM) to capture meal-related glycaemic fluctuations, which will provide
251 objective data on the effectiveness of dietary interventions in controlling postprandial
252 hyperglycaemia. Furthermore, the study design includes a robust process evaluation
253 component, which will assess both the fidelity and feasibility of the intervention. This
254 approach ensures that the findings will not only focus on clinical efficacy but also on the
255 practicalities of delivering the intervention in routine care.

256 One potential limitation of trial we foresee is attrition, which we aim to minimize
257 through regular follow-up, telephone consultations, and an ITT analysis.

258 If successful, the findings from this trial will have significant implications for diabetes
259 management, particularly in low-resource settings. The study will offer evidence on how

260 dietary interventions, combined with DSME, can be integrated into primary healthcare
261 systems in India, providing a low-cost, scalable approach to improving glycaemic
262 control. Moreover, the outcomes of this study will be crucial in informing future
263 guidelines and policies on dietary interventions for T2D management, particularly in
264 populations with traditionally carbohydrate-rich diets.[17,18]

265 In conclusion, this trial represents an important step toward optimizing diabetes care
266 through dietary modifications and self-management education. The results of this study
267 will provide valuable insights into the feasibility, safety, and effectiveness of low-
268 carbohydrate diets in controlling T2D, contributing to the growing body of evidence that
269 supports individualized, culturally appropriate dietary interventions in the management
270 of chronic diseases.

271 **Authors Contributions**

272 This is a collaborative research, each of the listed people provided important
273 intellectual contribution to study design. JC drafted the protocol. JC, SL, PG, JK, HDS and
274 MK drafted the final manuscript, while JC revised the final protocol. All authors
275 contributed to data analysis, drafting and revising the article, and have read and agreed
276 to the published version of the manuscript.

277 **Funding**

278 This work was supported by the Department of Health Research, Ministry of Health and
279 Family Welfare, Govt of India (grant number: R.11014/30/2023-GIA/HR).

280 **Conflicts of Interest:**

281 The author(s) declared no potential conflicts of interest with respect to the research,
282 authorship, and/or publication of this article.

283 **Patient and public involvement**

284 **Patients and/or the public were not involved in the design, or conduct, or reporting, or**
285 **dissemination plans of this research.**

286 **Reference**

- 287 1 Ong KL, Stafford LK, McLaughlin SA, *et al.* Global, regional, and national burden of diabetes
288 from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the
289 Global Burden of Disease Study 2021. *The Lancet*. 2023;402:203–34. doi: 10.1016/S0140-
290 6736(23)01301-6
- 291 2 Lin X, Xu Y, Pan X, *et al.* Global, regional, and national burden and trend of diabetes in 195
292 countries and territories: an analysis from 1990 to 2025. *Scientific Reports* 2020 10:1.
293 2020;10:1–11. doi: 10.1038/s41598-020-71908-9
- 294 3 Anjana RM, Unnikrishnan R, Deepa M, *et al.* Metabolic non-communicable disease health
295 report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). *Lancet*
296 *Diabetes Endocrinol*. 2023;11:474–89. doi: 10.1016/s2213-8587(23)00119-5
- 297 4 Sharma M, Kishore A, Roy D, *et al.* A comparison of the Indian diet with the EAT-Lancet
298 reference diet. *BMC Public Health*. 2020;20:1–13. doi: 10.1186/S12889-020-08951-
299 8/FIGURES/5
- 300 5 Goldenberg JZ, Johnston BC. Low and very low carbohydrate diets for diabetes remission. *The*
301 *BMJ*. 2021;373:m4743. doi: 10.1136/BMJ.N262
- 302 6 Van Zuuren EJ, Fedorowicz Z, Kuijpers T, *et al.* Effects of low-carbohydrate- compared with
303 low-fat-diet interventions on metabolic control in people with type 2 diabetes: a systematic
304 review including GRADE assessments. *Am J Clin Nutr*. 2018;108:300–31. doi:
305 10.1093/AJCN/NQY096
- 306 7 Gjuladin-Hellon T, Davies IG, Penson P, *et al.* Effects of carbohydrate-restricted diets on low-
307 density lipoprotein cholesterol levels in overweight and obese adults: a systematic review and
308 meta-analysis. *Nutr Rev*. 2019;77:161–80. doi: 10.1093/NUTRIT/NUY049
- 309 8 Meng Y, Bai H, Wang S, *et al.* Efficacy of low carbohydrate diet for type 2 diabetes mellitus
310 management: A systematic review and meta-analysis of randomized controlled trials. *Diabetes*
311 *Res Clin Pract*. 2017;131:124–31. doi: 10.1016/J.DIABRES.2017.07.006
- 312 9 Association AD. 5. Facilitating Behavior Change and Well-being to Improve Health
313 Outcomes: Standards of Medical Care in Diabetes—2020. *Diabetes Care*. 2020;43:S48–65.
314 doi: 10.2337/DC20-S005
- 315 10 Mohan V, Unnikrishnan R, Shobana S, *et al.* Are excess carbohydrates the main link to
316 diabetes & its complications in Asians? *Indian J Med Res*. 2018;148:531. doi:
317 10.4103/IJMR.IJMR_1698_18
- 318 11 Anjana RM, Srinivasan S, Sudha V, *et al.* Macronutrient Recommendations for Remission and
319 Prevention of Diabetes in Asian Indians Based on a Data-Driven Optimization Model: The
320 ICMR-INDIAB National Study. *Diabetes Care*. Published Online First: 19 August 2022. doi:
321 10.2337/DC22-0627

- 322 12 Chan AW, Tetzlaff JM, Altman DG, *et al.* SPIRIT 2013 Statement: Defining Standard Protocol
323 Items for Clinical Trials. *Ann Intern Med.* 2013;158:200. doi: 10.7326/0003-4819-158-3-
324 201302050-00583
- 325 13 Unwin D, Haslam D, Livesey G. It is the glycaemic response to, not the carbohydrate content
326 of food that matters in diabetes and obesity: The glycaemic index revisited. *Journal of*
327 *Metabolic Health.* 2016;1:1–9. doi: 10.4102/jir.v1i1.8
- 328 14 Wang LL, Wang Q, Hong Y, *et al.* The Effect of Low-Carbohydrate Diet on Glycemic Control
329 in Patients with Type 2 Diabetes Mellitus. *Nutrients.* 2018;10. doi: 10.3390/NU10060661
- 330 15 Francis JJ, Johnston M, Robertson C, *et al.* What is an adequate sample size? Operationalising
331 data saturation for theory-based interview studies. *Psychol Health.* 2010;25:1229–45. doi:
332 10.1080/08870440903194015
- 333 16 Green R, Milner J, Joy EJM, *et al.* Dietary patterns in India: A systematic review. *British*
334 *Journal of Nutrition.* 2016;116:142–8. doi: 10.1017/S0007114516001598
- 335 17 Rosenfeld RM, Kelly JH, Agarwal M, *et al.* Dietary Interventions to Treat Type 2 Diabetes in
336 Adults with a Goal of Remission: An Expert Consensus Statement from the American College
337 of Lifestyle Medicine. <https://doi.org/10.1177/15598276221087624>. 2022;16:342–62. doi:
338 10.1177/15598276221087624
- 339 18 Farhat G. Culturally Tailored Dietary Interventions for Improving Glycaemic Control and
340 Preventing Complications in South Asians with Type 2 Diabetes: Success and Future
341 Implications. *Healthcare.* 2023;11. doi: 10.3390/HEALTHCARE11081123

342

343

344

345

346

347

348

349

350


351

352

353

354

355



356

357

358

359

360 **Figure 1. Depicting the CONSORT flow chart of the trial.**

361

362 **Participant timeline**

Activities\Months	Year 1				Year 2			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Preparatory Phase (Govt Order, procurement, recruitment, training)								
Randomization of Health facilities (UPHC), Participant screening, recruitment, intervention and baseline assessment for glycaemic control, cardiorenal parameters and quality of life, initial systematic qualitative enquiry								
Follow up of patients (month 3, 6, 9 and 12)								
Outcome variables for glycaemic control, cardiorenal parameters and quality of life and systematic qualitative enquiry at month 12								
Analysis, report writing, publications including protocol paper and dissemination with stakeholders								

363

